Primary vs secondary hypogonadism: Where the problem starts and why it changes everything

Primary hypogonadism means low testosterone with high LH and FSH, while secondary hypogonadism means low testosterone with low or inappropriately normal LH and FSH. That distinction determines whether a man is more likely to need testosterone replacement or may be able to restore his own production with Enclomiphene. A low number alone cannot make that call, and treating every man the same can permanently compromise fertility.

Key takeaways

• Primary hypogonadism, also called hypergonadotropic hypogonadism, is defined by low testosterone with elevated LH and FSH, which means the pituitary is signaling strongly but the testes are not responding.^{[1] [2]}
• Secondary hypogonadism, also called hypogonadotropic hypogonadism, is defined by low testosterone with low or inappropriately normal LH and FSH, which means the testes may still be functional and stimulation therapy may work.^{[1] [2]}
• At Veedma, persistent symptoms plus morning testosterone assessment between 07:00 and 11:00 are interpreted with decision thresholds of 350 ng/dL for total testosterone and 100 pg/mL for free testosterone, with LH and FSH required for classification.
• Klinefelter syndrome is the most common genetic cause of primary hypogonadism, affects about 1 in 500 to 1,000 live male births, and fewer than 50% of cases are ever diagnosed.^[3]
• Functional hypogonadism is the most common real world type, and a 2013 systematic review found that weight loss can improve obesity associated hypogonadotropic hypogonadism, although the average hormonal gain is usually modest.^[4]
• Compensated hypogonadism means testosterone is still in range but LH is elevated, which may mark early or evolving gonadal failure rather than established testosterone deficiency.^[2]

How to classify the type of low testosterone

Primary vs secondary hypogonadism is defined by LH and FSH, not by testosterone alone.^{[1] [2]}

Male hypogonadism is a clinical syndrome that requires both persistent symptoms and biochemical evidence of testosterone deficiency. A low number alone is not enough, and symptoms alone are not enough either. For the full syndrome based definition, see What is low testosterone? The clinical definition most men and many doctors get wrong.

Gonadotropins are pituitary hormones that stimulate the testes. LH mainly drives testosterone production, and FSH mainly supports spermatogenesis. According to the Endocrine Society guideline, measuring gonadotropins is the essential step that separates testicular failure from hypothalamic or pituitary suppression.^[1]

Hypergonadotropic means LH and FSH are elevated. Hypogonadotropic means LH and FSH are low or inappropriately normal. The HPG axis is the brain to testes signaling loop that controls testosterone production. For a deeper explanation of that signaling pathway, see How the HPG axis works: the brain testes connection explained.

At Veedma, classification starts with a morning blood draw between 07:00 and 11:00, with direct free testosterone measured by equilibrium dialysis with LC MS/MS, total testosterone measured by LC MS/MS, and mandatory LH and FSH. We prioritize free testosterone because elevated SHBG can hide clinically important deficiency when total testosterone looks acceptable. For the full panel and workflow, see The complete low testosterone testing guide: what to order, when to test, and how to read results.

This is why two men with the same total testosterone, such as 200 ng/dL, may need opposite treatments. One has primary hypogonadism and needs replacement because the testes cannot respond. The other has secondary or functional hypogonadism and may recover endogenous production with Enclomiphene, which preserves spermatogenesis instead of suppressing it.^{[1] [5]}

Primary hypogonadism means testicular failure

Primary hypogonadism means the testes cannot produce enough testosterone despite strong pituitary stimulation.^{[1] [2]}

Primary hypogonadism is the classic hypergonadotropic hypogonadism pattern. In plain language, the brain is signaling aggressively, but the testes cannot answer. The laboratory signature is low testosterone with elevated LH and FSH. In the European Male Ageing Study, this pattern was biologically distinct from secondary and compensated forms.^[2]

Congenital causes of primary hypogonadism

Congenital means present from birth. The most prevalent genetic cause is Klinefelter syndrome, usually 47,XXY. According to a 2013 clinical review, Klinefelter syndrome affects about 1 in 500 to 1,000 live male births, and fewer than 50% of cases are ever diagnosed.^[3]

Other congenital causes listed in major endocrine guidance include cryptorchidism, bilateral anorchia, myotonic dystrophy, disorders of sex development, and sickle cell disease.^[1]

Acquired causes of primary hypogonadism

Acquired means the damage happened after birth. Important causes include chemotherapy, especially alkylating agents, testicular irradiation, surgical removal of the testes, severe testicular trauma, orchitis including mumps orchitis, testicular torsion, environmental toxins, and alcohol related testicular damage or cirrhosis.^[1]

These causes share the same endpoint. Leydig cells, the testicular cells that make testosterone, are damaged or absent, so raising pituitary output further does not restore production.

Why treatment is different in primary hypogonadism

Only testosterone replacement can reliably correct symptomatic testosterone deficiency in true primary hypogonadism.^[1]

That is the central treatment implication of hypergonadotropic hypogonadism. Stimulation therapies work only if the testes can still respond. In primary disease, they usually cannot. Exogenous testosterone can improve symptoms and biochemical deficiency, but it suppresses LH and FSH further and can impair any remaining spermatogenesis. That is why fertility counseling must happen before treatment starts.

Secondary hypogonadism means central signal failure

Secondary hypogonadism means the testes may still work, but the hypothalamus or pituitary is not sending enough signal.^{[1] [2]}

Secondary hypogonadism is also called hypogonadotropic hypogonadism. The laboratory pattern is low testosterone with low or inappropriately normal LH and FSH. The key phrase is “inappropriately normal.” If testosterone is truly low, LH and FSH should rise. When they do not, the central signal is failing.

Common causes of secondary hypogonadism

According to the Endocrine Society guideline, secondary hypogonadism is common in clinical practice and has several distinct cause groups.^[1]

• Drug induced causes, including opiates, exogenous testosterone or anabolic steroids, GnRH agonists or antagonists, glucocorticoids, and estrogens
• Localized causes, including pituitary tumors, traumatic brain injury, pituitary surgery or irradiation, and hyperprolactinemia
• Systemic causes, including type 2 diabetes, metabolic syndrome, obesity, chronic organ failure, eating disorders, endurance overtraining, and acute illness

These categories matter because some are reversible, some are treatable at the source, and some require long term hormonal management.

Why Enclomiphene fits secondary hypogonadism

Enclomiphene can restore testosterone production in many men with secondary hypogonadism because the testes remain capable of responding to LH and FSH.^[5]

Enclomiphene is a selective estrogen receptor modulator. In plain language, it blocks estrogen feedback at the hypothalamus, which increases GnRH release, raises pituitary LH and FSH output, and tells the testes to produce testosterone naturally. A 2014 BJU International trial found that Enclomiphene increased endogenous testosterone while preserving sperm counts, which is the opposite of what happens with testosterone replacement.^[5]

This is why treatment choice changes everything. A man with low or normal LH and low testosterone, especially when LH is below 8 mIU/mL, may be an Enclomiphene candidate if symptoms persist and no organic contraindication is found. When fertility is the primary goal, hCG and FSH are additional options because they also stimulate testicular function rather than shutting it down.^[1]

Functional hypogonadism is the most common reversible pattern

Functional hypogonadism is low testosterone caused by reversible suppression of an otherwise intact HPG axis.^{[1] [4]}

Functional hypogonadism is the most common real world type of low testosterone. It is diagnosed when no recognized organic damage is found in the hypothalamus, pituitary, or testes, and low testosterone is driven instead by comorbidities and reversible stressors. Inflammatory cytokines from chronic disease, adipocytokines from excess fat mass, and higher estradiol production in adipose tissue can all suppress the axis without destroying it.^[4]

What drives functional hypogonadism

The main drivers are obesity, metabolic syndrome, type 2 diabetes, medications, chronic organ failure, overtraining, disordered eating, and acute illness. This is still a form of secondary hypogonadism by location, but clinically it deserves separate attention because the axis is suppressed, not structurally broken.^[1]

Why Enclomiphene and lifestyle are the logical first step

Functional hypogonadism should first be treated by addressing the underlying cause, but the most practical first line strategy is often Enclomiphene plus lifestyle modification.

A 2013 systematic review and meta analysis found that body weight loss can reverse obesity associated hypogonadotropic hypogonadism and improve gonadotropin signaling.^[4] The problem is durability. In routine practice, the testosterone increase from lifestyle change alone is often only about 1 to 2 nmol/L, and 60% to 86% of lost weight is regained within 3 years. Because the axis is intact, Enclomiphene can “wake up” that suppressed system while the man works on the drivers that caused the problem in the first place.

This is the most important practical distinction in the modern types of low testosterone. If a reversible, intact axis is treated as if it were irreversible testicular failure, the patient may be placed on lifelong testosterone therapy unnecessarily and lose fertility in the process.

Androgen resistance and decreased bioactivity form a third category

Androgen resistance and decreased androgen bioactivity can produce androgen deficiency even when total testosterone does not look low.^[6]

This is the third category that many low testosterone discussions miss. The problem is not always how much testosterone is present. Sometimes the problem is how well tissues can use it. The androgen receptor is the cellular docking site for testosterone and dihydrotestosterone. Five alpha reductase is the enzyme that converts testosterone to dihydrotestosterone in target tissues.

Congenital forms of androgen resistance

According to Quigley and colleagues, congenital androgen receptor defects can range from complete androgen insensitivity to milder undervirilization syndromes.^[6] Other congenital causes of reduced androgen action include 5 alpha reductase deficiency, Kennedy disease, and variations in androgen receptor CAG repeat length that can alter tissue responsiveness.

Acquired forms of decreased androgen bioactivity

Acquired forms include finasteride and dutasteride, which block 5 alpha reductase, spironolactone and other antiandrogens that block receptor activity, elevated SHBG that reduces free testosterone availability, and coeliac disease, which has been linked to impaired androgen status in some men.^{[1] [6]}

This is why free testosterone matters. A man can have a total testosterone result that looks “normal” but still have low androgen bioactivity because too little hormone is freely available to tissues. At Veedma, direct free testosterone by equilibrium dialysis with LC MS/MS is used to avoid missing this pattern.

Compensated hypogonadism is a warning pattern

Compensated hypogonadism means testosterone remains normal while LH is elevated.^[2]

In plain language, the pituitary is working harder than usual to keep testosterone in range. The European Male Ageing Study identified this pattern as distinct from overt primary and secondary hypogonadism.^[2]

The clinical significance is still uncertain. It may represent early or evolving gonadal failure, or a state in which the axis is under strain but not yet failing. What it does not represent is confirmed testosterone deficiency by itself, because normal testosterone means the biochemical criterion for overt hypogonadism has not been met.

That is why compensated hypogonadism is best viewed as a warning sign worth monitoring, especially if symptoms are emerging or risk factors for primary testicular failure are present.

Age of onset changes how hypogonadism looks

The age at which hypogonadism begins determines how dramatically it affects development and symptoms.^{[1] [7]}

The same endocrine problem can look completely different depending on whether it begins in fetal life, around puberty, or in adult life. According to Kaufman and Vermeulen, adult onset androgen deficiency is often subtle and easily confused with ordinary aging, unlike earlier onset forms that alter development itself.^[7]

Fetal onset

Fetal onset can range from an externally female phenotype to milder virilization defects, depending on when the androgen signal fails and whether the problem lies in testosterone production, conversion to dihydrotestosterone, or androgen receptor function.^[6]

Pre and peri pubertal onset

Pre pubertal and peri pubertal onset can present with delayed puberty, poor virilization, small testes, and eunuchoid body proportions. These forms are usually easier to recognize because expected developmental milestones do not occur.^[1]

Post pubertal and adult onset

Post pubertal or adult onset hypogonadism, including late onset hypogonadism, is usually milder in appearance and often mistaken for stress, weight gain, or aging. Sexual symptoms, reduced physical performance, fat gain, and mood changes may accumulate slowly rather than appearing abruptly. For a fuller symptom framework, see How low testosterone symptoms show up differently at every age.

This age effect is one more reason that classification must be clinical, not purely numeric. The same testosterone value can mean very different things in a man who never completed puberty, a young man with secondary suppression from drugs or obesity, and an older man with emerging testicular failure.

Myth vs fact

Myth: A low testosterone number alone diagnoses hypogonadism

Fact: Male hypogonadism requires persistent symptoms plus biochemical evidence. Once deficiency is confirmed, LH and FSH determine whether the problem is primary, secondary, or compensated.^{[1] [2]}

Myth: All types of low testosterone are treated the same way

Fact: Primary hypogonadism usually requires testosterone replacement, while secondary and especially functional hypogonadism may respond to Enclomiphene because the testes can still be stimulated.^{[1] [5]}

Myth: Normal LH rules out a brain signal problem

Fact: In a man with low testosterone, a “normal” LH can be abnormal because it is inappropriately low for the degree of deficiency. That pattern supports secondary hypogonadism.^{[1] [2]}

Myth: TRT is fertility neutral

Fact: Exogenous testosterone suppresses pituitary gonadotropins and spermatogenesis. For men with secondary or functional hypogonadism who may want future fertility, stimulation therapy is often the more appropriate first move.^{[1] [5]}

Myth: Normal total testosterone means androgen action is normal

Fact: Androgen resistance, 5 alpha reductase defects, receptor antagonism, and reduced free testosterone availability can all produce androgen deficiency despite nonlow total testosterone.^[6]

Bottom line

Where low testosterone starts determines whether treatment should replace testosterone or stimulate natural production. Primary hypogonadism points to testicular failure and usually requires replacement, while secondary and functional hypogonadism can often be approached with fertility preserving stimulation, especially Enclomiphene, when the axis is intact. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers a thorough diagnostic workup with an advanced lab panel measured by LC MS/MS, or a review of existing lab results that you already have, including uploads from services such as Function Health. Licensed providers build individualized treatment plans with Enclomiphene as first line when appropriate, add the Enclomiphene plus Tadalafil combination tablet when erection or urinary symptoms are also present, and provide ongoing monitoring with protocol adjustments based on symptoms and follow up labs.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. The Journal of clinical endocrinology and metabolism. 2010;95:1810-8. PMID: 20173018
3. Groth KA, Skakkebæk A, Høst C, et al. Clinical review: Klinefelter syndrome–a clinical update. The Journal of clinical endocrinology and metabolism. 2013;98:20-30. PMID: 23118429
4. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European journal of endocrinology. 2013;168:829-43. PMID: 23482592
5. Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs : the investigational drugs journal. 2009;12:109-19. PMID: 19204885
6. Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrine reviews. 1995;16:271-321. PMID: 7671849
7. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrine reviews. 2005;26:833-76. PMID: 15901667